Allogene Therapeutics targets new approach to autoimmune conditions with ALLO-329

Allogene Therapeutics targets new approach to autoimmune conditions with ALLO-329
Allogene debuts ALLO-329 therapy

Allogene Therapeutics has introduced ALLO-329, an investigational allogeneic CAR-T therapy developed to transform treatment options for autoimmune diseases.

Powered by Dagger technology, the therapy aims to minimize or eliminate the need for lymphodepletion, a common step in traditional cell therapy protocols. ALLO-329 represents a potential breakthrough in cell therapy by seeking a safer and more accessible solution for patients with autoimmune conditions. Further research and clinical validation will be required before the treatment can move toward wider adoption.

The introduction of ALLO-329 not only builds on Allogene Therapeutics’ momentum in advancing CAR-T therapies, but also reaffirms emerging hope for severe autoimmune disease patients, a theme explored in the discussion of a potential breakthrough for patients with critical unmet needs. Further context on the innovative role of Dagger technology in transforming autoimmune disease care can be found through the lens of ALLO-329’s development and strategic direction.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.